BioAge Labs (NASDAQ:BIOA) Trading 8.7% Higher – Should You Buy?

BioAge Labs, Inc. (NASDAQ:BIOA) shares traded up 8.7% during mid-day trading on Friday . The stock traded as high as $17.76 and last traded at $17.8730. 82,522 shares were traded during trading, a decline of 86% from the average session volume of 586,678 shares. The stock had previously closed at $16.45.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Oppenheimer assumed coverage on shares of BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price target on the stock. Roth Mkm assumed coverage on shares of BioAge Labs in a research report on Wednesday, May 27th. They set a “buy” rating and a $36.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. Finally, Needham & Company LLC assumed coverage on shares of BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.50.

BioAge Labs Price Performance

The stock’s 50 day moving average is $17.19 and its two-hundred day moving average is $17.03. The stock has a market capitalization of $801.93 million, a PE ratio of -7.52 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.19. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. The firm had revenue of $2.77 million for the quarter. On average, equities analysts predict that BioAge Labs, Inc. will post -2.68 earnings per share for the current year.

Hedge Funds Weigh In On BioAge Labs

Several hedge funds have recently added to or reduced their stakes in BIOA. Russell Investments Group Ltd. purchased a new position in BioAge Labs in the third quarter valued at approximately $27,000. CWM LLC increased its stake in BioAge Labs by 39.9% in the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after purchasing an additional 1,053 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in BioAge Labs by 85.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares during the last quarter. Walleye Capital LLC purchased a new position in BioAge Labs in the second quarter valued at approximately $64,000. Finally, Bank of America Corp DE increased its stake in BioAge Labs by 46.3% in the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after purchasing an additional 3,517 shares during the last quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.